Dr. Alinari is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
460 W 10th Ave
Columbus, OH 43210Phone+1 614-293-3989Fax+1 614-293-9789
Education & Training
Ohio State University HospitalFellowship, Hematology and Medical Oncology, 2013 - 2016- Ohio State University HospitalResidency, Internal Medicine, 2011 - 2013
University of BolognaPhD, Experimental Therapeutics for Hematologic Malignancies, 2008 - 2011
University of Florence Faculty of MedicineClass of 1998
Certifications & Licensure
OH State Medical License 2011 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
Clinical Trials
- Ibrutinib and Nivolumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Start of enrollment: 2016 Dec 20
- A Study of TAK-981 Given With Rituximab in Adults With Relapsed or Refractory CD20-Positive Non-Hodgkin Lymphoma Start of enrollment: 2019 Oct 15
Roles: Principal Investigator
- Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma Start of enrollment: 2023 Mar 06
Roles: Contact, Sponsor-Investigator, Principal Investigator
Publications & Presentations
PubMed
- 13 citationsPembrolizumab and its role in relapsed/refractory classical Hodgkin’s lymphoma: evidence to date and clinical utility:Polina Shindiapina, Lapo Alinari
Therapeutic Advances in Hematology. 2018-03-05 - 201 citationsPhase II Trial of Proteasome Inhibitor Bortezomib in Patients With Relapsed or Refractory Cutaneous T-Cell LymphomaPier Luigi Zinzani, Gerardo Musuraca, Monica Tani, Vittorio Stefoni, Enrica Marchi
Journal of Clinical Oncology. 2007-09-20 - 4 citationsPhase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma.Robert A Baiocchi, Lapo Alinari, Mark E Lustberg, Thomas S Lin, Pierluigi Porcu
Cancer. 2011-06-01
Abstracts/Posters
- Brentuximab Vedotin (BV) and Lenalidomide (Len) in Relapsed and Refractory (r/r) Cutaneous (CTCL) and Peripheral (PTCL) T-Cell Lymphomas; A Planned Interim Analysis of...Lapo Alinari, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- A Phase I Study of Nivolumab and Lenalidomide in Relapsed/ Refractory B Cell LymphomaLapo Alinari, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- PRMT5 Inhibition Drives Therapeutic Vulnerability to BCL-2 Inhibition with Venetoclax and Provides Rationale for Combination Therapy in Mantle Cell LymphomaLapo Alinari, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Join now to see all
Press Mentions
Recipients of AACR Research Funding & Fellowships 1993–2017September 8th, 2017
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
